Ginkgo Bioworks Holdings, Inc. (DNA) Fair Value 2026

DNA · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.8 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-27, Ginkgo Bioworks Holdings, Inc. (DNA) trades at $7.26. QOC: 5.8/10. Value Trap Risk: 26/100 (LOW). 1/13 models active.

Key Facts

Ticker
DNA
Price
$7.26
Quality Score
5.8/10
Value Trap Risk
26/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +49.0% upside with 30% confidence
Risk: Limited model coverage (1/13) may reduce confidence

What Fair Value Does Each Model Give DNA?

1 Intrinsic Value Models vs. Current Price ($7.26)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $10.82 +49.0%

All Models Active

All 1 models are displayed above.

What Is Ginkgo Bioworks Holdings, Inc. (DNA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Ginkgo Bioworks Holdings, Inc.'s intrinsic value is estimated at a median fair value of $10.82. At a current market price of $7.26, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +49.0%.

What Do the Models Say About DNA?

1 of 13 models are currently active for DNA. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does DNA Rank in Biotechnology?

Among 620 Biotechnology stocks, DNA ranks #172 by Quality of Company score. CirclFi's QOC score of 5.8/10 evaluates 32 fundamental signals. A score of 5.8 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Ginkgo Bioworks Holdings, Inc. competes in an environment where cash runway (months) often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is DNA a Value Trap?

CirclFi's Value Trap algorithm assigns DNA a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Ginkgo Bioworks Holdings, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Ginkgo Bioworks Holdings, Inc.'s fundamental quality profile registers 5.8/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every DNA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across DNA's 1 active models, average confidence is 30%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Ginkgo Bioworks Holdings, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

NAMSNewAmsterdam Pharma Company N.V.QOC 5.8ABSIAbsci CorporationQOC 5.8PRLDPrelude Therapeutics IncorporatedQOC 5.8CCCCC4 Therapeutics, Inc.QOC 5.8MRVIMaravai LifeSciences Holdings, Inc.QOC 5.8CUECue Biopharma, Inc.QOC 5.8GHRSGH Research PLCQOC 5.0ACHVAchieve Life Sciences, Inc.QOC 4.3INVAInnoviva, Inc.QOC 8.6EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: NAMS · ABSI · PRLD · CCCC · MRVI · CUE · GHRS · ACHV · INVA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to DNA?

6 companies across all industries closest to DNA’s Quality of Company score of 5.8/10.

SPHLSpringview Holdings LtdQOC 5.8FBGLFBS Global LimitedQOC 5.8UUUUniversal Safety Products, IncQOC 5.8BCICBCP Investment Corp.QOC 5.8OZVNOZ Vision Inc.QOC 5.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SPHL · FBGL · UUU · BCIC · OZVN · NVDA

Where Does DNA Sit in CirclFi's Biotechnology Rankings?

DNA is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Ginkgo Bioworks Holdings, Inc.’s Valuation?

What is Ginkgo Bioworks Holdings, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Ginkgo Bioworks Holdings, Inc. (DNA). The Quality of Company score is 5.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is DNA overvalued or undervalued right now?

At $7.26, 1 of 1 active models suggest DNA may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Ginkgo Bioworks Holdings, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.8 mean for DNA?

Ginkgo Bioworks Holdings, Inc.'s QOC of 5.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on DNA?

CirclFi analyzes DNA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is DNA a value trap in 2026?

Ginkgo Bioworks Holdings, Inc.'s Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Ginkgo Bioworks Holdings, Inc. (DNA) a Quality of Company score of 5.8/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/DNA/ · Methodology
Primary sources for this DNA valuation
  • Financial statements: Ginkgo Bioworks Holdings, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001830214) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for DNA as of ; valuations recomputed .